Showing 1371-1380 of 1735 results for "".
- Presbia Abandons Flexivue Microlens, Lays Off All But 3https://modernod.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/Presbia said it spiked its Flexivue microlens development program in the face of FDA headwinds, laying off all but three of its employees as it seeks investors to bail it out, according to a Mass Device report. Earlier this month, the Irvine, Calif.-based company
- Oyster Point Announces Results of Phase 3 Trial of OC-01 Nasal Spray for Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-results-of-phase-3-trial-of-oc-01-nasal-spray-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2477743/Oyster Point Pharma announced positive topline results from the phase 3 ONSET-2 study in dry eye disease. The ONSET-2 trial met the primary endpoint, where a greater percentage of subjects treate
- Caren Mason, CEO of Starr Surgical, Named to Top 50 Healthcare Technology CEOs Of 2020https://modernod.com/news/caren-mason-ceo-of-starr-surgical-named-to-top-50-healthcare-technology-ceos-of-2020/2477827/The Healthcare Technology Report announced The Top 50 Healthcare Technology CEOs of 2020. Data on each CEO’s professional background was gathered and they were assessed across several key areas, including breadth of leadership experience in the healthcare technology industry, level of exper
- Wills Eye Takes Top Honors For ‘Excellence In Patient Care’ In Annual Best Hospitals’ Listhttps://modernod.com/news/wills-eye-takes-top-honors-for-excellence-in-patient-care-in-annual-best-hospitals-list/2476781/In the 2019-2020 U.S. News & World Report Best Hospitals Rankings, board certified physicians throughout the U.S. voted Wills Eye a top center of excellence where they would refer their most complex patients. “The news of this peer recognition is tremendously gratifying an
- AAO: Proof of COVID-19 Vaccination Required for All Registrants Attending Annual Meeting in New Orleanshttps://modernod.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/The American Academy of Ophthalmology’s board of trustees has decided that proof of COVID-19 vaccination will be required for all registrants attending the Academy’s annual meeting in New Orleans. Every AAO 2021 attendee, all Academy staff, exhibitors, and guests will be required to
- EyeMD EMR 2.0 All-in-One Platform Unveiled at AAO Virtualhttps://modernod.com/news/eyemd-emr-healthcare-systems-to-unveil-the-eyemd-emr-2-0-all-in-one-platform-at-aao-virtual/2478542/EyeMD EMR Healthcare Systems will debut EyeMD EMR 2.0, an all-in-one EMR, PM, and PACS system at the American Academy of Ophthalmology (AAO) Virtual Conference, taking place Nov. 13–15, 2020. EyeMD EMR 2.0 now includes EMR, PM and PACS functionality in one streamlined offering. EyeMD EMR P
- Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-patient-savings-program-where-eligible-patients-can-pay-as-little-as-0-for-tyrvaya-nasal-spray/2480401/Oyster Point Pharma announced it has launched a patient support program called TEAMTyrvaya where eligible1 patients can pay as little as $0 for Tyrvaya (varenicline solution) Nasal Spray 0.03 mg. The FDA, approved Tyrvaya Nasal Spray for the treatment of
- FDA Accepts Oyster Point’s Filing of NDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-oyster-points-filing-new-drug-application-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478928/Oyster Point Pharma announced that the FDA has accepted its new drug application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act (PDUFA) target action date for OC-01 (varenicline) nasal spray is October 17, 2
- Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint-in-phase-2-mystic-trial-in-subjects-with-dry-eye-disease/2477225/Oyster Point Pharma announced positive topline results from its phase 2 MYSTIC study in dry eye disease. Results showed a statistically significant improvement in Schirmer’s score from baseline at Day 84 in both doses as compared to control.
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe